BioVie Inc

Change company Symbol lookup

Select an option...

BIVI BioVie Inc

GME GameStop Corp

DCO Ducommun Inc

QSI Quantum-Si Inc

TLS Telos Corp

ONB Old National Bancorp

TIG Trean Insurance Group Inc

NVDA NVIDIA Corp

DICE Dice Therapeutics Inc

NUSI Nationwide Nasdaq-100® Risk-Managed Income ETF

Go

BioVie Inc. is a clinical-stage company. The Company is developing drug therapies to treat chronic debilitating conditions, including liver disease and neurological and neuro-degenerative disorders and certain cancers. In liver disease, the Company's orphan drug candidate BIV201 (continuous infusion terlipressin) is developed as a future treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), hepatitis, and alcoholism. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.